PN: B411155

COMPONENTS

45x Ab-conjugated beads (S4P8 - NHP IL-1RA Ab-bead). PN: B411155A. One vial containing 100 µL of anti-NHP IL-1RA conjugated to AimPlex Bead S4P8.

25x Biotin-detection Ab (NHP IL-1RA Biotin-dAb). PN: B411155B. One vial containing 100 µL of biotinylated anti-NHP IL-1RA.

Lyophilized Standard Mix-NHP Group 1 Panel B. PPN: HG10011. One vial containing lyophilized recombinant Eotaxin, IL-1β, IL-1RA, IL-8, IL-12p70, IL-22, IP-10, MCP-1, MCP-3, and RANTES. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying NHP IL-1RA.  Can be multiplexed with other analytes in Human Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 2,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in NHP Group 1: Negligible

Sample volume: 15 µL/test

Description:

The interleukin-1 receptor antagonist (IL-1RA) was initially called the IL-1 inhibitor and was discovered separately in 1984 by two independent laboratories.  IL-1RA, is an agent that binds non-productively to the cell surface interleukin-1 receptor (IL-1R). IL-1R is the same receptor that binds interleukin 1 (IL-1). Hence IL-1RA prevents IL-1 from sending a signal to that cell.  A polymorphism of this gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer. Mutations in the IL1RN gene results in a rare disease called deficiency of the interleukin-1–receptor antagonist (DIRA). Variants of the IL1RN gene is also associated with risk of schizophrenia. Elevated levels of IL1RN has been found in serum of schizophrenia patients. An interleukin 1 receptor antagonist is used in the treatment of rheumatoid arthritis, an autoimmune disease in which IL-1 plays a key role. It is commercially produced as Anakinra, which is a human recombinant form of IL-1RA. 

References:

1.       Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB (July 1992). "The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci". Genomics 13 (3): 654–7. doi:10.1016/0888-7543(92)90137-H. PMID 1386337.

2.       Patterson D, Jones C, Hart I, Bleskan J, Berger R, Geyer D, Eisenberg SP, Smith MF, Arend WP (January 1993). "The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region". Genomics 15 (1): 173–6. doi:10.1006/geno.1993.1025. PMID 8432529.

3.       Dinarello CA (December 1994). "The interleukin-1 family: 10 years of discovery". FASEB J. 8 (15): 1314–25. PMID 8001745.

4.       Perrier S, Darakhshan F, Hajduch E (November 2006). "IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?". FEBS Lett. 580 (27): 6289–94. doi:10.1016/j.febslet.2006.10.061. PMID 17097645.